欢迎来到天天文库
浏览记录
ID:34391770
大小:115.39 KB
页数:5页
时间:2019-03-05
《Can_the_pharmaceutical_industry_reduce_attrition_rates.pdf》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、PERSPECTIVESbyanumberofexplanations:theindustryisOPINIONcurrentlyattackingdiseasesofgreatcom-plexity;theentrybarfornewdrugsishigherCanthepharmaceuticalindustrybecausetheyareoftencompetingwithenhancedstandardofcare;and/ortheregu-latoryauthoritiesaremoredemanding.reduceattritionrates?Whatev
2、erthecase,thesefeaturesdefinethenewplayingfieldonwhichtheindustryhastocompetetoproduceNCEsthatarerequiredIsmailKolaandJohnLandistoachievenecessarygrowth;anexaminationofthefactorsthatimpactR&DsuccessisThepharmaceuticalindustryfacesapproximately9%.Similarly,in2003largethereforecrucialinterm
3、sofdevisingaconsiderablechallenges,bothpoliticallypharmastockpriceswereamongtheworststrategythatcanbuildapipelineneededtoandfiscally.Politically,governmentsaroundperformingsectorontheNewYorkStocksustainthebusinesscaseforlargepharma.theworldaretryingtocontaincostsand,Exchange(NYSE),withana
4、verageapprecia-ashealthcarebudgetsconstituteaverytionof0.3%,comparedwiththegeneralDefiningthebusinesscasesignificantpartofgovernmentalspending,S&P500marketappreciationof26%.AtArecentsurveybyAccenture3definedthethesecostsarethesubjectofintensepresenttheaveragepricetoearnings(P/E)businessca
5、seforlargepharmaceuticalcom-scrutiny.IntheUnitedStates,drugcostsratiooflargepharmastocksistradingatapaniesintermsofNCEsrequiredtoremainaarealsothesubjectofintensepoliticaldiscounttotheentiremarket.Bycontrast,growthcompanyonthebasisoftheircurrentdiscourse.Thisarticledealswiththefiscalthiss
6、ectorhashistoricallytradedatapre-revenuesandtheirdesiredpercentagegrowthpressuresthatfacetheindustryfromthemiumtotherestofthemarket,mainly(TABLE1).Onthebasisofthiscalculation,perspectiveofR&D.Whatimpingesonbecauseofpipelinevaluations.Pfizer,withpharmaceuticalrevenuesin2003productivity?How
7、canweimprovecurrentofapproximatelyUS$45billion,willneedtoreducedR&Dproductivity?Depressingapprovalratesgenerateapproximatelyninehigh-qualityIn2002,theUSFDAapprovalsofNCEswereNCEsperannum.GlaxoSmithKline,withTheaveragelifeexpectancyofhumanshaslowerthanatanyothertimei
此文档下载收益归作者所有
点击更多查看相关文章~~